Table 2. Baseline characteristics of the SPMS and PPMS subjects included in the analysis.
| IMPACT (n = 219) | OLYMPUS (n = 147) | |
| Characteristic | ||
| Age | 47.9 (7.7) a | 49.6 (8.7) |
| Gender, Female, n (%) | 141 (64) | 81 (55) |
| Number of relapses in past year | 0.38 (0.49) | N/A |
| Gd-enhancing lesions, count >0, n (%) | 75 (34.4) | 37 (25.2) |
| Disease Duration (years) | ||
| Since first symptom | 16.7 (9.0) | 9.0 (6.8) |
| Since diagnosis | 10.5 (7.5) | 3.8 (4.2) |
| Prior treatment with INF-β or GA, n (%) | ||
| Ended >90 days before trial entry | 2 (1)b | 45 (30.6) |
| Ended ≤90 days before trial entry | 0 | 6 (4.1) |
| EDSS score | 5.2 (1.1) | 4.7 (1.4) |
| MSFC components | ||
| T25FW (sec) | 14.6 (15.4) | 11.6 (15.8) |
| 9HPT (sec) | 33.2 (30.0) | 29.9 (13.0) |
| PASAT-3 (sec) | 46.8 (12.3) | 46.7 (12.6) |
a
All of the values are mean (SD), except Gender and Prior MS treatment, and Gd-enhancing lesions.
b
These two subjects with prior MS treatments were on GA, which ended >180 days before trial entry.